Douglas Emmett (DEI) recently posted first quarter 2026 results that combined a small net loss with stronger funds from operations, record leasing volumes and expanding medical office exposure, giving investors fresh data on the stock.

The stock has reacted to the Q1 2026 earnings beat on funds from operations and record leasing activity with a 26.37% 1 month share price return. However, the 1 year total shareholder return of 11.62% decline and 5 year total shareholder return of 51.73% decline show that longer term performance has been weak and any positive momentum is still developing from a low base.

If you are looking beyond Douglas Emmett and want more ideas in real assets and infrastructure, this is a good moment to see which companies stand out in the 36 power grid technology and infrastructure stocks

With the stock up sharply over the past month, trading slightly above the average analyst target yet still screening as having an intrinsic discount, the key question is whether Douglas Emmett is undervalued or whether the market is already pricing in future growth.

Most Popular Narrative: 4.2% Overvalued

Analysts following Douglas Emmett see fair value at $11.55 compared with the last close at $12.03, putting the stock slightly above their modeled level and shining a light on how medical expansion and redevelopment feed into that view.

The redevelopment of Douglas Emmett's Studio Plaza office building from single-tenant to multi-tenant use is expected to increase occupancy and leasing activity, positively impacting both revenues and net margins. Planned construction activities at the Barrington Plaza residential property and permits for redevelopment projects are forecasted to boost long-term income streams, thereby enhancing revenue growth and earnings stability.

Curious how modest revenue growth, thinner margins and a very high implied earnings multiple all fit together in one story of fair value and medical expansion? Potential growth, tight assumptions, and a bold long term earnings profile sit at the center of this narrative.

Result: Fair Value of $11.55 (OVERVALUED)

However, there is still clear downside risk if office occupancy remains weak or higher interest costs continue to pressure FFO and delay any payoff from redevelopment projects.

Another Angle On Valuation

Analysts see Douglas Emmett as about 4.2% overvalued at $12.03 versus their $11.55 consensus, yet the SWS DCF model points the other way, with an estimated future cash flow value of $16.75 that is about 28.2% above the current price. Which story do you trust more, cautious earnings multiples or long term cash flows?

Next Steps

With signals mixed across valuation, growth and risk, this is a good time to review the numbers yourself and consider your options before sentiment shifts further, starting by weighing the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If you stop here, you only see one stock story. Use this moment to scan fresh opportunities that might fit your goals better than Douglas Emmett.

• Zero in on quality by reviewing companies that pass tight value and fundamentals checks with the 51 high quality undervalued stocks
• Prioritise resilience and capital protection with the 72 resilient stocks with low risk scores
• Get ahead of the crowd by searching for future standouts using the screener containing 23 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.